Letters to Agencies – Prescription Drugs

2013 2018 2019

ERIC Submits Comments on Maine Biosimilar Bill

Today, ERIC submitted comments to the Maine House Committee on Health Coverage, Insurance and Financial Services regarding Legislative Document 659, which would allow pharmacists to make biosimilar substitutions… More

Alert: ERIC Submits Comments on Arkansas Biosimilar Bill

Today, ERIC submitted comments to the Arkansas House Public Health, Welfare and Labor Committee on House Bill 1269, which would allow pharmacists to make biosimilar substitutions… More

ERIC Submits Comments to HHS on the President’s “American Patients First” Blueprint

Today, ERIC submitted comments to the Department of Health and Human Services (HHS) in response to its Request for Information related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs… More

ERIC Submits Comments on Mississippi’s Part 2640 Proposed Rules

On behalf of The ERISA Industry Committee (ERIC), thank you for accepting input from interested stakeholders as you consider the Mississippi State Board of Medical Licensure proposed rules for Part 2640… More

ERIC Submits Comments on Proposed Changes to Medicare Prescription Drug Program

The ERISA Industry Committee (ERIC) submitted comments to the Centers for Medicare & Medicaid Services (CMS) on proposed changes to the Medicare prescription drug program… More

ERIC Urges CMS to Reconsider Restrictive Requirements on Part D Automatic Prescription Refills

ERIC, along with several other employer business groups, on June 11 wrote to the Centers for Medicare and Medicaid Services urging the agency to reconsider unnecessarily restrictive requirements on automatic prescription refill programs under Medicare Part D. … More

2013 2018 2019